Alzheimer's Disease and Testing Innovations: Bill Morice, M.D., Ph.D. - Insights
Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss testing innovations for Alzheimer’s...
What Happens Next? Lab-Developed Test Rule Vacated: Bill Morice, M.D., Ph.D. - Insights
Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the recent court judgment on...
Summertime Pathogens: Bill Morice, M.D., Ph.D. - Insights
of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss pathogens commonly found...
Viruses and Variants: Dr. Bill Morice - Insights
William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly...
Global Industry Activities: Bill Morice, M.D., Ph.D. - Insights
Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss insights from Dr. Morice’s...
Mayo Clinic Laboratory and Pathology Research Roundup: January 9 - Insights
inflammatory disease, on treatment with daily subcutaneous injections of 600 mg of recombinant interleukin-1 receptor antagonist (IL-1Ra) protein, anakinra, since the age of 28, who presented with golf-ball size...
newborn-screen-elevated-c0-c16-c18.pdf
© Mayo Foundation for Medical Education and Research (MFMER). All rights reserved. 08/20/23 Newborn screen results: ■ Elevated or normal free carnitine (C0) ■ Elevated C0/C16+C18 ratio Perform: Plasma ammonia, blood gas, glucose,...
Mayo Clinic Laboratory and Pathology Research Roundup: January 23 - Insights
administered in recurrent GBM patients either at the resection cavity (Group A), or, intratumorally on day 1, followed by a second dose administered in the resection cavity after tumor resection on day 5 (Group...
Final Rule on LDTs May Be Coming Soon: Bill Morice, M.D., Ph.D. - Insights
Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the Food and Drug Administration’s...
2020 COVID-19 Recap: Dr. Bill Morice - Insights
William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly...